With hundreds of known cancer types and a steady increase in the incidence of cancer worldwide, researchers need the latest information and resources to help unravel the complexities of the disease. Our cancer research resource library is here to support your research and discovery, wherever it leads.
Historically cancer treatment has taken a ‘one size fits all’ approach. However, it’s clear that every cancer is different and being able to understand and anticipate differences in drug response, resistance, and efficacy of therapies at the cellular level may provide better treatment options.
Too many candidates, too little time. The lack of robust, rapid, high-throughput assays to identify and qualify potential therapeutic targets in areas such as cancer research continues to cost valuable time. What if you could increase assay throughput without compromising sensitivity, obtain more data points from each sample and eliminate tedious wash steps? Find out how AlphaLISA® assay technology,
Various cytokines are secreted during an active immune response that can have modulatory effects on target cell populations, including interferon gamma and several interleukins
Optical-based in vivo imaging of vascular changes and vascular leak is an emerging modality for studying altered physiology in a variety of different cancers and inflammatory states. A number of fluorescent imaging probes that circulate with the blood, but have no target selectivity, have been used to detect tumor leakiness as an indication of abnormal tumor vasculature.
The ability to access and search across public genome datasets efficiently, can have tremendous impact on biomarker discovery. Simplify the complexity around search, retrieval and analysis of large public datasets such as The Cancer Genome Atlas (TCGA) to gain valuable insights for Oncology biomarker detection.
The field of immuno-oncology is complex and researchers are faced with many challenges to better understand the relationship between the immune system, tumor biology and tumor microenvironment. We offer a wide range of tools to support and advance your immuno-oncology research to help you redefine and develop personalized, life-changing immunotherapies
Every patient has the ability to respond to immune therapy but too often tumors fail to regress due to either primary or acquired resistance. Here, we discuss the mechanisms behind immune evasion and how understanding the barriers to effective treatment in each individual patient can create a roadmap to a more effective and personalized treatment strategy with the goal of prolonged survival.
Although targeted therapies for CLL exist, some patients harbor subpopulations of resistant leukemia cells that mediate disease recurrence. Understanding the heterogeneity of CLL tumor cells is therefore important for the development of novel treatment strategies.
The application of immunotherapy – specifically immune checkpoint inhibitors – for cancer treatment has burgeoned over the past decade and revolutionized the management of certain types of cancer. Yet, it has become well-understood that most patients do not respond to immunotherapy, or they develop resistance to such treatment.
Intra-tumoral heterogeneity, whereby distinct tumor cell populations with different molecular and phenotypic profiles form within the same tumor, is observed in human cancers. This phenomenon poses a significant hurdle for cancer therapy as some evolving cell types are resistant to treatment.
Recent reports of precision medicine trials demonstrating patient benefit have been disappointingly low. In order to deliver more personalized treatments, researchers need to look beyond pure genomics processes to a multi-dimensional assessment utilizing both genomic and image-based diagnostics.
